Drug General Information (ID: DDIDYOHP3N)
Drug Name			Trastuzumab emtansine		Drug Info		Ticagrelor		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics/Her2 Inhibitors				Antiplatelet Agents

Mechanism of Trastuzumab emtansine-Ticagrelor Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Trastuzumab emtansine				Ticagrelor
Mechanism		Risk of bleeding Antiplatelet effects				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Trastuzumab emtansine and Ticagrelor

Recommended Action
Management		Caution is recommended and additional monitoring should be considered if trastuzumab emtansine must be used with anticoagulant or antiplatelet drugs. In general, monitoring of platelet counts is recommended prior to each dose of trastuzumab emtansine.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Kadcyla (ado-trastuzumab). Genentech, South San Francisco, CA.